Diagnostic significance of peritumoral enhancement in distinguishing between muscle-invasive and non-muscle-invasive bladder cancer

被引:0
|
作者
Takeuchi, Mitsuru [1 ,2 ]
Higaki, Atsushi [2 ]
Kojima, Yuichi [2 ]
Ono, Kentaro [2 ]
Maruhisa, Takuma [2 ]
Yokoyama, Takatoshi [2 ]
Watanabe, Hiroyuki [2 ]
Yamamoto, Akira [2 ]
Tamada, Tsutomu [2 ]
机构
[1] Radiolonet Tokai, Nagoya, Japan
[2] Kawasaki Med Sch, Kurashiki, Japan
关键词
Urinary bladder neoplasms; Multiparametric magnetic resonance imaging; peritumoral enhancement; VI-RADS; Dynamic contrast-enhanced imaging; ENDOMETRIAL CANCER; ACCURACY; MRI;
D O I
10.1007/s00261-024-04658-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective The aim of this study was to assess the prevalence of peritumoral enhancement (PTE) in patients with muscle-invasive bladder cancer (MIBC) and non-MIBC (NMIBC) and to propose a modified diagnostic criterion for Vesical Imaging Reporting and Data System (VI-RADS) that incorporates PTE. Materials and methods This retrospective study included 95 patients with bladder cancer (age, 72 +/- 11; 77 men; 36 MIBCs and 59 Non-MIBCs) who underwent multiparametric MRI in our referral center between 2011 and 2023. The images were interpreted by four radiologists. The readers classified the possibility of muscle layer invasion into categories 1-5, based on the VI-RADS categorical diagnostic criterion. PTE was defined as a linear contrast enhancement observed at the edge of tumor invasion which is convex outward from the normal bladder wall and contrasts more than the normal muscle layer and tumor. A modified VI-RADS that upgrades the final VI-RADS category to 4 if PTE is present when the original VI-RADS category is 3 or less was proposed. The frequency of PTE in the MIBC and NMIBC groups was compared using the Fisher's exact test. Sensitivity and specificity for the diagnosis of MIBC were compared with the original VI-RADS using McNemar test. Pathologic diagnosis was used as the reference standard. Results PTE was present in 70-81% (25/36-29/36) of MIBC and absent in 92-98% (54/59-58/59) of non-MIBC. For all readers, the PTE was significantly more frequent (p < 0.001) in the MIBC group than the NMIBC group. The sensitivities of modified VI-RADS (75.0-86.1%) were significantly higher than those of original VI-RADS (41.7-55.6%) (p = 0.002-0.008). The specificity of modified VI-RADS (91.5-98.3%) were not statistically different from original VI-RADS (98.3-100%). Conclusions In conclusion, PTE is a highly specific finding for MIBC. modified VI-RADS incorporating PTE increases sensitivity for MIBC.
引用
收藏
页码:1679 / 1688
页数:10
相关论文
共 50 条
  • [21] Muscle-Invasive Bladder Cancer
    Hasan, Shaakir
    Chhabra, Arpit M.
    Choi, J. Isabelle
    Simone, Charles B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : 309 - 310
  • [22] Muscle-invasive bladder cancer
    Buchler, Jakob
    Gschwend, Juergen E.
    Retz, Margitta
    Schmid, Sebastian C.
    UROLOGE, 2021, 60 (06): : 769 - 775
  • [23] Metabolomics analysis of non-muscle invasive and muscle-invasive bladder cancer.
    Sahu, Divya
    Lotan, Yair
    Wittman, Bryan
    Neri, Bruce
    Hansel, Donna E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [24] Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy
    Chen, Shuo
    Zhu, Shanshan
    Cui, Xiaoyu
    Xu, Wenbin
    Kong, Chuize
    Zhang, Zhe
    Qian, Wei
    BIOMEDICAL OPTICS EXPRESS, 2019, 10 (07) : 3533 - 3544
  • [25] Quantitative Immunofluorescence Evaluation of PD-L1 Expression in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer
    T. A. Bogush
    K. S. Spiridonova
    E. A. Bogush
    A. N. Grishanina
    A. M. Scherbakov
    M. I. Volkova
    Z. M. Safarov
    V. B. Matveev
    V. S. Kosorukov
    Moscow University Chemistry Bulletin, 2023, 78 : 338 - 343
  • [26] Quantitative Immunofluorescence Evaluation of PD-L1 Expression in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer
    Bogush, T. A.
    Spiridonova, K. S.
    Bogush, E. A.
    Grishanina, A. N.
    Scherbakov, A. M.
    Volkova, M. I.
    Safarov, Z. M.
    Matveev, V. B.
    Kosorukov, V. S.
    MOSCOW UNIVERSITY CHEMISTRY BULLETIN, 2023, 78 (06) : 338 - 343
  • [27] Study on non-muscle-invasive Bladder Cancer Therapy
    Rexer, H.
    UROLOGE, 2016, 55 (04): : 528 - 531
  • [28] TIMELINE Landmarks in non-muscle-invasive bladder cancer
    Mertens, Laura S.
    Neuzillet, Yann
    Horenblas, Simon
    van Rhijn, Bas W. G.
    NATURE REVIEWS UROLOGY, 2014, 11 (08) : 476 - 480
  • [29] Diagnosis and treatment of non-muscle-invasive bladder cancer
    Mostafid, Hugh
    Bryan, Richard T.
    Rees, Jonathan
    TRENDS IN UROLOGY & MENS HEALTH, 2015, 6 (02) : 23 - +
  • [30] Metastasis development in non-muscle-invasive bladder cancer
    Leyderman, Michael
    Chandrasekar, Thenappan
    Grivas, Petros
    Li, Roger
    Bhat, Seetharam
    Basnet, Alina
    Shapiro, Oleg
    Jacob, Joseph
    Daneshvar, Michael A.
    Kord, Eyal
    Bratslavsky, Gennady
    Goldberg, Hanan
    NATURE REVIEWS UROLOGY, 2024,